AKT1 and colorectal cancer: In PIK3CA-mutant colorectal cancer lines, copanlisib, another class 1 selective inhibitor, has been shown to increase apoptosis, decrease cell growth, and decrease phosphorylated AKT expression in cells [18,19,20].